Apitoria completes acquisition of A1 Biochem Group CRO business

Aurobindo Pharma's wholly owned subsidiary Apitoria Pharma has completed the acquisition of the Contract Research Services business of A1 Biochem Group. Apitoria now holds 80 percent in A1 Biochem Labs India, with the remaining 20 percent held by the former promoter. A1 Labs India, through its US unit, has also acquired 100 percent of A1 Biochem Labs LLC in the USA. The deal gives Apitoria access to a CRO platform with over 50 clients and 800 plus completed projects, helping build an integrated CRDMO platform.